Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Biphenotypic, Acute 2Patient Preference 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 7fludarabine 6Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6ruxolitinib 5fludarabine phosphate 5Melphalan 5venetoclax 4Peripheral Blood Stem Cell Transplantation 4itacitinib 3Specimen Handling 3Sirolimus 3Granulocyte Colony-Stimulating Factor 3Cytarabine 3Biopsy 3Azacitidine 3navitoclax 2luspatercept 2Etoposide 2Daunorubicin 2Busulfan 2Antilymphocyte Serum 2thymoglobulin 1selinexor 1quizartinib 1pomalidomide 1plerixafor 1pevonedistat 1parsaclisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myeloproliferative Disorders × decitabine and cedazuridine drug combination × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡